keyword
https://read.qxmd.com/read/38498721/progress-in-primary-progressive-aphasia-a-review
#21
REVIEW
Andrew Kertesz, Elizabeth Finger, David G Munoz
We present a review of the definition, classification, and epidemiology of primary progressive aphasia (PPA); an update of the taxonomy of the clinical syndrome of PPA; and recent advances in the neuroanatomy, pathology, and genetics of PPA, as well as the search for biomarkers and treatment. PPA studies that have contributed to concepts of language organization and disease propagation in neurodegeneration are also reviewed. In addition, the issues of heterogeneity versus the relationships of the clinical phenotypes and their relationship to biological, pathological, and genetic advances are discussed, as is PPA's relationship to other conditions such as frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, Pick disease, and amyotrophic lateral sclerosis...
March 1, 2024: Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology
https://read.qxmd.com/read/38407533/frequency-and-outcomes-of-gastrostomy-insertion-in-a-longitudinal-cohort-study-of-atypical-parkinsonism
#22
JOURNAL ARTICLE
Christopher Kobylecki, Viorica Chelban, Yee Yen Goh, Emilia Michou, Riona Fumi, Marte Theilmann Jensen, Rahema Mohammad, Alyssa Costantini, Nirosen Vijiaratnam, Samantha Pavey, Nicola Pavese, P Nigel Leigh, James B Rowe, Michele T Hu, Alistair Church, Huw R Morris, Henry Houlden
BACKGROUND: Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) show a high prevalence and rapid progression of dysphagia, which is associated with reduced survival. Despite this, the evidence base for gastrostomy is poor, and the optimal frequency and outcomes of this intervention are not known. We aimed to characterise the prevalence and outcomes of gastrostomy in patients with these three atypical parkinsonian disorders. METHOD: We analysed data from the natural history and longitudinal cohorts of the PROSPECT-M-UK study with up to 60 months of follow-up from baseline...
February 26, 2024: European Journal of Neurology
https://read.qxmd.com/read/38405025/two-distinct-degenerative-types-of-nigrostriatal-dopaminergic-neuron-in-the-early-stage-of-parkinsonian-disorders
#23
JOURNAL ARTICLE
Tomoya Kawazoe, Keizo Sugaya, Yasuhiro Nakata, Masato Okitsu, Kazushi Takahashi
INTRODUCTION: The present study characterized the degeneration of nigrostriatal dopaminergic neurons in the early stages of parkinsonian disorders using integrative neuroimaging analysis with neuromelanin-sensitive MRI and 123 I-FP-CIT dopamine transporter (DAT) SPECT. METHODS: Thirty-one, 30, and 29 patients with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) with abnormal specific binding ratio (SBR) in either hemisphere (mean ± 2SD), and parkinsonism-predominant multiple system atrophy (MSA-P), respectively, were enrolled...
2024: Clinical parkinsonism & related disorders
https://read.qxmd.com/read/38392951/planimetric-and-volumetric-brainstem-mri-markers-in-progressive-supranuclear-palsy-multiple-system-atrophy-and-corticobasal-syndrome-a-systematic-review-and-meta-analysis
#24
REVIEW
Maria-Evgenia Brinia, Ioanna Kapsali, Nikolaos Giagkou, Vasilios C Constantinides
BACKGROUND: Various MRI markers-including midbrain and pons areas (Marea , Parea ) and volumes (Mvol , Pvol ), ratios (M/Parea , M/Pvol ), and composite markers (magnetic resonance imaging Parkinsonism Indices 1,2; MRPI 1,2)-have been proposed as imaging markers of Richardson's syndrome (RS) and multiple system atrophy-Parkinsonism (MSA-P). A systematic review/meta-analysis of relevant studies aiming to compare the diagnostic accuracy of these imaging markers is lacking. METHODS: Pubmed and Scopus were searched for studies with >10 patients (RS, MSA-P or CBS) and >10 controls with data on Marea , Parea , Mvol , Pvol , M/Parea , M/Pvol , MRPI 1, and MRPI 2...
December 19, 2023: Neurology International
https://read.qxmd.com/read/38369623/total-patient-delay-a-comparison-of-patient-and-clinician-health-system-delays-in-the-diagnosis-of-progressive-supranuclear-palsy-and-corticobasal-syndrome
#25
JOURNAL ARTICLE
Diane M A Swallow, Peter Murchie, Carl E Counsell
BACKGROUND: Early diagnosis in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) is important for clinical care and key to developing successful disease-modifying agents. The patient-dependent phases of decision-making made before contact with a healthcare professional have been inadequately studied. OBJECTIVES: To evaluate the patient-dependent phases of decision-making from symptom onset, comparing this to clinician and/or health system delays within the overall diagnostic pathway...
February 18, 2024: Movement Disorders Clinical Practice
https://read.qxmd.com/read/38347942/correction-to-clinical-course-of-pathologically-confirmed-corticobasal-degeneration-and-corticobasal-syndrome
#26
COMMENT
(no author information available yet)
[This corrects the article DOI: 10.1093/braincomms/fcad296.].
2024: Brain communications
https://read.qxmd.com/read/38309321/nucleus-basalis-of-meynert-degeneration-predicts-cognitive-decline-in-corticobasal-syndrome
#27
JOURNAL ARTICLE
Daniele Urso, Salvatore Nigro, Benedetta Tafuri, Roberto De Blasi, Joana B Pereira, Giancarlo Logroscino
BACKGROUND: Cognitive changes are common in corticobasal syndrome (CBS) and significantly impact quality of life and caregiver burden. However, there is a scarcity of studies investigating the neural substrates of cognitive changes in CBS, and currently, reliable predictors of cognitive impairment are lacking. The nucleus basalis of Meynert (NbM), which serves as the primary source of cortical cholinergic innervation, has been functionally associated with cognition. This study aimed to explore whether patients with CBS exhibit reduced NbM volumes compared to healthy controls and whether NbM degeneration can serve as a predictor of cognitive impairment in CBS patients...
February 1, 2024: Biological Psychiatry
https://read.qxmd.com/read/38290377/deep-vein-thrombosis-and-its-risk-factors-in-neurodegenerative-diseases-a-markedly-higher-incidence-in-parkinson-s-disease
#28
JOURNAL ARTICLE
Takahiro Takeda, Akihiro Koreki, Sayuri Kokubun, Yumiko Saito, Ai Ishikawa, Sagiri Isose, Kimiko Ito, Kimihito Arai, Kazuo Kitagawa, Satoshi Kuwabara, Kazuhiro Honda
BACKGROUND: Information on the incidence and risk factors of deep vein thrombosis (DVT) in neurodegenerative diseases is limited. We aimed to determine the incidence of DVT among neurodegenerative disorders (amyotrophic lateral sclerosis [ALS], Parkinson's disease [PD], multiple system atrophy [MSA], and progressive supranuclear palsy [PSP]-corticobasal syndrome [CBS]) and the risk factors for the development of DVT. METHODS: Overall, 229 hospitalized patients with neurodegenerative diseases (65 patients with ALS, 61 with PD, 53 with MSA, and 50 with PSP-CBS) were included in this study...
February 15, 2024: Journal of the Neurological Sciences
https://read.qxmd.com/read/38287807/dissecting-the-clinical-heterogeneity-and-genotype-phenotype-correlations-of-mapt-mutations-a-systematic-review
#29
Cristina Villa, Elisa Pellencin, Aurora Romeo, Giorgio Giaccone, Giacomina Rossi, Sara Prioni, Paola Caroppo
BACKGROUND: Microtubule-associated protein tau ( MAPT ) mutations are one of the main causes of genetic Frontotemporal dementia (FTD) and are characterised by high clinical heterogeneity. A behavioural variant of FTD is the principal phenotype, but other rarer phenotypes are described, mostly reported as single cases. In this review, we provide an overview of the clinical phenotypes associated with MAPT mutations in order to define their characteristics and explore genotype-phenotype correlations...
January 16, 2024: Frontiers in Bioscience (Landmark Edition)
https://read.qxmd.com/read/38268757/monash-alfred-protocol-for-assessment-of-atypical-parkinsonian-syndromes-map-aps
#30
JOURNAL ARTICLE
Timothy P Siejka, Kelly L Bertram, Huiliang M Tang, Dominic Thyagarajan, Terence J O'Brien, Helmut Butzkueven, Lucy Vivash, Ian H Harding
INTRODUCTION: Atypical parkinsonian syndromes (APS) are rare neurodegenerative syndromes for which parkinsonism is one significant feature. APS includes progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal syndrome (CBS). The diagnosis of APS remains reliant on clinical features with no available diagnostic or prognostic biomarker. Clinical scales remain the gold standard assessment measures in clinical trials and research. The lack of standardised approach for research cohorts has contributed to shortcomings in disease understanding and limits collaboration between researchers...
2024: BMJ neurology open
https://read.qxmd.com/read/38256599/glucose-metabolism-and-cognitive-decline-in-progressive-supranuclear-palsy-and-corticobasal-syndrome-a-preliminary-study
#31
JOURNAL ARTICLE
Natalia Madetko-Alster, Dagmara Otto-Ślusarczyk, Marta Struga, Michał Kutyłowski, Agnieszka Drzewińska, Karolina Duszyńska-Wąs, Bartosz Migda, Piotr Alster
Multiple studies have analyzed the possible correlations between diabetes and Alzheimer's disease. Less is known about the context of cognitive deterioration among patients with atypical Parkinsonian syndromes and glucose metabolism impairment. The aim of this study was to evaluate the association between the impaired glucose metabolism and cognitive decline among patients with progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The study included 22 patients with PSP and CBS with disease durations varying from 3 to 6 years...
January 14, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38216704/the-enigma-of-depression-in-corticobasal-degeneration-a-frequent-but-poorly-understood-co-morbidity
#32
REVIEW
Kurt A Jellinger
Depression is one of the most frequent neuropsychiatric symptoms in corticobasal degeneration (CBD), a rare, sporadic, and late-onset progressive neurodegenerative disorder of unknown etiology. It is clinically characterized by a levodopa-poorly responsible akinetic-rigid syndrome, apraxia, limb dystonia, cognitive, mood, behavioral, and language disorders. This 4-repeat (4R) tauopathy is morphologically featured by asymmetric frontoparietal atrophy, neuronal loss, and gliosis in cortex and subcortex including substantia nigra, ballooned/achromatic neurons with filamentous 4R tau aggregates in cortex and striatum, widespread thread-like structures, pathognomonic "astroglial plaques", "tufted astrocytes", and numerous "coiled bodies" (in astrocytes and oligodendroglia) in cerebral white matter...
March 2024: Journal of Neural Transmission
https://read.qxmd.com/read/38194490/patients-with-neurodegenerative-proteinopathies-exhibit-altered-tryptophan-metabolism-in-the-serum-and-cerebrospinal-fluid
#33
JOURNAL ARTICLE
Michal Kaleta, Eva Hényková, Kateřina Menšíková, David Friedecký, Aleš Kvasnička, Kateřina Klíčová, Dorota Koníčková, Miroslav Strnad, Petr Kaňovský, Ondřej Novák
Some pathological conditions affecting the human body can also disrupt metabolic pathways and thus alter the overall metabolic profile. Knowledge of metabolic disturbances in specific diseases could thus enable the differential diagnosis of otherwise similar conditions. This work therefore aimed to comprehensively characterize changes in tryptophan metabolism in selected neurodegenerative diseases. Levels of 18 tryptophan-related neuroactive substances were determined by high throughput and sensitive ultrahigh-performance liquid chromatography-tandem mass spectrometry in time-linked blood serum and cerebrospinal fluid samples from 100 age-matched participants belonging to five cohorts: healthy volunteers ( n = 21) and patients with Lewy body disease (Parkinson's disease and dementia with Lewy bodies; n = 31), four-repeat tauopathy (progressive supranuclear palsy and corticobasal syndrome; n = 10), multiple system atrophy ( n = 13), and Alzheimer's disease ( n = 25)...
January 9, 2024: ACS Chemical Neuroscience
https://read.qxmd.com/read/38173024/neuropathological-hints-from-csf-and-serum-biomarkers-in-corticobasal-syndrome-cbs-a-systematic-review
#34
REVIEW
Giulia Remoli, Edoardo Dalmato Schilke, Andrea Magi, Antonio Ancidoni, Giulia Negro, Fulvio Da Re, Maura Frigo, Martina Giordano, Nicola Vanacore, Marco Canevelli, Carlo Ferrarese, Lucio Tremolizzo, Ildebrando Appollonio
Corticobasal syndrome (CBS) is a clinical syndrome determined by various underlying neurodegenerative disorders requiring a pathological assessment for a definitive diagnosis. A literature review was performed following the methodology described in the Cochrane Handbook for Systematic Reviews to investigate the additional value of traditional and cutting-edge cerebrospinal fluid (CSF) and serum/plasma biomarkers in profiling CBS. Four databases were screened applying predefined inclusion criteria: (1) recruiting patients with CBS; (2) analyzing CSF/plasma biomarkers in CBS...
January 4, 2024: Neurological research and practice
https://read.qxmd.com/read/38165362/association-of-neurofilament-light-chain-18-f-pi-2620-tau-pet-tspo-pet-and-clinical-progression-in-patients-with-%C3%AE-amyloid-negative-cbs
#35
JOURNAL ARTICLE
Carla Palleis, Nicolai Franzmeier, Endy Weidinger, Alexander M Bernhardt, Sabrina Katzdobler, Stephan Wall, Christian Ferschmann, Stefanie Harris, Julia Schmitt, Sebastian Schuster, Johannes Gnörich, Anika Finze, Gloria Biechele, Simon Lindner, Nathalie L Albert, Peter Bartenstein, Osama Sabri, Henryk Barthel, Rainer Rupprecht, Brigitte Nuscher, Andrew W Stephens, Boris-Stephan Rauchmann, Robert Perneczky, Christian Haass, Matthias Brendel, Johannes Levin, Günter U Höglinger
BACKGROUND AND OBJECTIVES: Corticobasal syndrome (CBS) with underlying 4-repeat tauopathy is a progressive neurodegenerative disease characterized by declining cognitive and motor functions. Biomarkers for assessing pathologic brain changes in CBS including tau-PET, 18 kDa translocator protein (TSPO)-PET, structural MRI, neurofilament light chain (NfL), or glial fibrillary acidic protein (GFAP) have recently been evaluated for differential diagnosis and disease staging, yet their association with disease trajectories remains unclear...
January 9, 2024: Neurology
https://read.qxmd.com/read/38155526/probable-4-repeat-tauopathy-criteria-predict-brain-amyloid-negativity-distinct-clinical-features-and-fdg-pet-mri-neurodegeneneration-patterns-in-corticobasal-syndrome
#36
JOURNAL ARTICLE
Jacy Bezerra Parmera, Camila de Godoi Carneiro, Isabel Junqueira de Almeida, Marcos Castello Barbosa de Oliveira, Pedro Melo Barbosa, Adalberto Studart-Neto, Carla Rachel Ono, Ricardo Nitrini, Carlos Alberto Buchpiguel, Egberto Reis Barbosa, Sonia Maria Dozzi Brucki, Artur Martins Coutinho
BACKGROUND: Corticobasal syndrome (CBS) is associated with diverse underlying pathologies, including the four-repeat (4R)-tauopathies. The Movement Disorders Society (MDS) criteria for progressive supranuclear palsy (PSP) proposed the novel category "probable 4R-tauopathy" to address the phenotypic overlap between PSP and corticobasal degeneration (CBD). OBJECTIVES: To investigate the clinical ability of the MDS-PSP criteria for probable 4R-tauopathy in predicting a negative amyloid-PET in CBS...
December 18, 2023: Movement Disorders Clinical Practice
https://read.qxmd.com/read/38106054/functional-network-collapse-in-neurodegenerative-disease
#37
Jesse A Brown, Alex J Lee, Kristen Fernhoff, Taylor Pistone, Lorenzo Pasquini, Amy B Wise, Adam M Staffaroni, Maria Luisa Mandelli, Suzee E Lee, Adam L Boxer, Katherine P Rankin, Gil D Rabinovici, Maria Luisa Gorno Tempini, Howard J Rosen, Joel H Kramer, Bruce L Miller, William W Seeley
Cognitive and behavioral deficits in Alzheimer's disease (AD) and frontotemporal dementia (FTD) result from brain atrophy and altered functional connectivity. However, it is unclear how atrophy relates to functional connectivity disruptions across dementia subtypes and stages. We addressed this question using structural and functional MRI from 221 patients with AD (n=82), behavioral variant FTD (n=41), corticobasal syndrome (n=27), nonfluent (n=34) and semantic (n=37) variant primary progressive aphasia, and 100 cognitively normal individuals...
December 6, 2023: bioRxiv
https://read.qxmd.com/read/38103086/analysis-of-biomarkers-in-speculative-cns-enriched-extracellular-vesicles-for-parkinsonian-disorders-a-comprehensive-systematic-review-and-diagnostic-meta-analysis
#38
REVIEW
Hash Brown Taha, Aleksander Bogoniewski
BACKGROUND AND OBJECTIVE: Parkinsonian disorders, including Parkinson's disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS), exhibit overlapping early-stage symptoms, complicating definitive diagnosis despite heterogeneous cellular and regional pathophysiology. Additionally, the progression and the eventual conversion of prodromal conditions such as REM behavior disorder (RBD) to PD, MSA, or DLB remain challenging to predict...
April 2024: Journal of Neurology
https://read.qxmd.com/read/38090279/clinical-course-of-pathologically-confirmed-corticobasal-degeneration-and-corticobasal-syndrome
#39
JOURNAL ARTICLE
Ikuko Aiba, Yuichi Hayashi, Takayoshi Shimohata, Mari Yoshida, Yuko Saito, Koichi Wakabayashi, Takashi Komori, Masato Hasegawa, Takeshi Ikeuchi, Aya M Tokumaru, Keita Sakurai, Shigeo Murayama, Kazuko Hasegawa, Toshiki Uchihara, Yasuko Toyoshima, Yufuko Saito, Ichiro Yabe, Satoshi Tanikawa, Keizo Sugaya, Kentaro Hayashi, Terunori Sano, Masaki Takao, Motoko Sakai, Harutoshi Fujimura, Hiroshi Takigawa, Tadashi Adachi, Ritsuko Hanajima, Osamu Yokota, Tomoko Miki, Yasushi Iwasaki, Michio Kobayashi, Nobutaka Arai, Takuya Ohkubo, Takanori Yokota, Keiko Mori, Masumi Ito, Chiho Ishida, Masaharu Tanaka, Jiro Idezuka, Masato Kanazawa, Kenju Aoki, Masashi Aoki, Takafumi Hasegawa, Hirohisa Watanabe, Atsushi Hashizume, Hisayoshi Niwa, Keizo Yasui, Keita Ito, Yukihiko Washimi, Eiichiro Mukai, Akatsuki Kubota, Tatsushi Toda, Kenji Nakashima
The clinical presentation of corticobasal degeneration is diverse, while the background pathology of corticobasal syndrome is also heterogeneous. Therefore, predicting the pathological background of corticobasal syndrome is extremely difficult. Herein, we investigated the clinical findings and course in patients with pathologically, genetically and biochemically verified corticobasal degeneration and corticobasal syndrome with background pathology to determine findings suggestive of background disorder. Thirty-two patients were identified as having corticobasal degeneration...
2023: Brain communications
https://read.qxmd.com/read/38090278/clinical-course-in-corticobasal-syndrome-and-corticobasal-degeneration-implications-for-diagnosis-and-management
#40
JOURNAL ARTICLE
Robert I McGeachan, Declan King
This scientific commentary relates to 'Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome', by Aiba et al . (https://doi.org/10.1093/braincomms/fcad296).
2023: Brain communications
keyword
keyword
113873
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.